newsfilter
← Latest News
GlobeNewswire·

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prelude's once daily,